167 related articles for article (PubMed ID: 19887911)
21. The Roles of MDM2 and MDMX in Cancer.
Karni-Schmidt O; Lokshin M; Prives C
Annu Rev Pathol; 2016 May; 11():617-44. PubMed ID: 27022975
[TBL] [Abstract][Full Text] [Related]
22. MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation.
Qi DL; Cobrinik D
Oncogene; 2017 Mar; 36(13):1760-1769. PubMed ID: 27748758
[TBL] [Abstract][Full Text] [Related]
23. MDM4 enhances p53 stability by promoting an active conformation of the protein upon DNA damage.
Di Conza G; Mancini F; Buttarelli M; Pontecorvi A; Trimarchi F; Moretti F
Cell Cycle; 2012 Feb; 11(4):749-60. PubMed ID: 22374672
[TBL] [Abstract][Full Text] [Related]
24. Puzzling over MDM4-p53 network.
Mancini F; Di Conza G; Monti O; Macchiarulo A; Pellicciari R; Pontecorvi A; Moretti F
Int J Biochem Cell Biol; 2010 Jul; 42(7):1080-3. PubMed ID: 20417304
[TBL] [Abstract][Full Text] [Related]
25. MDM4 is a key therapeutic target in cutaneous melanoma.
Gembarska A; Luciani F; Fedele C; Russell EA; Dewaele M; Villar S; Zwolinska A; Haupt S; de Lange J; Yip D; Goydos J; Haigh JJ; Haupt Y; Larue L; Jochemsen A; Shi H; Moriceau G; Lo RS; Ghanem G; Shackleton M; Bernal F; Marine JC
Nat Med; 2012 Aug; 18(8):1239-47. PubMed ID: 22820643
[TBL] [Abstract][Full Text] [Related]
26. Mouse models of Mdm2 and Mdm4 and their clinical implications.
Xiong S
Chin J Cancer; 2013 Jul; 32(7):371-5. PubMed ID: 23327795
[TBL] [Abstract][Full Text] [Related]
27. CEP-1347 Targets MDM4 Protein Expression to Activate p53 and Inhibit the Growth of Glioma Cells.
Mitobe Y; Nakagawa-Saito Y; Togashi K; Suzuki S; Sugai A; Matsuda KI; Sonoda Y; Kitanaka C; Okada M
Anticancer Res; 2022 Oct; 42(10):4727-4733. PubMed ID: 36192008
[TBL] [Abstract][Full Text] [Related]
28. The expression of MDM2, MDM4, p53 and p21 in myeloid neoplasms and the effect of MDM2/MDM4 dual inhibitor.
Eskandari M; Shi Y; Liu J; Albanese J; Goel S; Verma A; Wang Y
Leuk Lymphoma; 2021 Jan; 62(1):167-175. PubMed ID: 32924682
[TBL] [Abstract][Full Text] [Related]
29. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage.
Chen L; Gilkes DM; Pan Y; Lane WS; Chen J
EMBO J; 2005 Oct; 24(19):3411-22. PubMed ID: 16163388
[TBL] [Abstract][Full Text] [Related]
30. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development.
Terzian T; Wang Y; Van Pelt CS; Box NF; Travis EL; Lozano G
Mol Cell Biol; 2007 Aug; 27(15):5479-85. PubMed ID: 17526734
[TBL] [Abstract][Full Text] [Related]
31. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.
Toledo F; Wahl GM
Nat Rev Cancer; 2006 Dec; 6(12):909-23. PubMed ID: 17128209
[TBL] [Abstract][Full Text] [Related]
32. Regulation of kidney development by the Mdm2/Mdm4-p53 axis.
El-Dahr S; Hilliard S; Saifudeen Z
J Mol Cell Biol; 2017 Feb; 9(1):26-33. PubMed ID: 28096292
[TBL] [Abstract][Full Text] [Related]
33. Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties.
Prodosmo A; Giglio S; Moretti S; Mancini F; Barbi F; Avenia N; Di Conza G; Schünemann HJ; Pistola L; Ludovini V; Sacchi A; Pontecorvi A; Puxeddu E; Moretti F
J Mol Med (Berl); 2008 May; 86(5):585-96. PubMed ID: 18335186
[TBL] [Abstract][Full Text] [Related]
34. Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53.
Xie X; Lozano G; Siddik ZH
Oncogene; 2016 Sep; 35(36):4798-806. PubMed ID: 26876197
[TBL] [Abstract][Full Text] [Related]
35. Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4.
Grier JD; Xiong S; Elizondo-Fraire AC; Parant JM; Lozano G
Mol Cell Biol; 2006 Jan; 26(1):192-8. PubMed ID: 16354690
[TBL] [Abstract][Full Text] [Related]
36. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas.
Valentin-Vega YA; Barboza JA; Chau GP; El-Naggar AK; Lozano G
Hum Pathol; 2007 Oct; 38(10):1553-62. PubMed ID: 17651783
[TBL] [Abstract][Full Text] [Related]
37. Otub1 stabilizes MDMX and promotes its proapoptotic function at the mitochondria.
Chen Y; Wang YG; Li Y; Sun XX; Dai MS
Oncotarget; 2017 Feb; 8(7):11053-11062. PubMed ID: 28035068
[TBL] [Abstract][Full Text] [Related]
38. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development.
Xiong S; Van Pelt CS; Elizondo-Fraire AC; Liu G; Lozano G
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3226-31. PubMed ID: 16492743
[TBL] [Abstract][Full Text] [Related]
39. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo.
Francoz S; Froment P; Bogaerts S; De Clercq S; Maetens M; Doumont G; Bellefroid E; Marine JC
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3232-7. PubMed ID: 16492744
[TBL] [Abstract][Full Text] [Related]
40. Mdmx as an essential regulator of p53 activity.
Marine JC; Jochemsen AG
Biochem Biophys Res Commun; 2005 Jun; 331(3):750-60. PubMed ID: 15865931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
